RE: Why was Soft Tissue Sarcoma highlighted in RNS?23 Feb 2023 13:47
The US Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Avacta Group's lead pre|CISION drug candidate, AVA6000, to treat soft tissue sarcoma.6 Sept 2022